Why Did Glucotrack Stock Surge 12% Pre-Market Today?
Synopsis
The company has received patents for its continuous blood glucose monitoring system.
Glucotrack, Inc. (GCTK) announced on Thursday that it has secured three new U.S. patents for its continuous blood glucose monitoring (CBGM) platform.
The patents are expected to boost the company’s intellectual property portfolio as it moves its long-term implantable monitoring system closer to commercialization.
Following the update, Glucotrack stock traded over 12% higher in Thursday’s premarket.
New Patents Strengthen IP
The US Patent and Trademark Office issued Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258, covering critical aspects of Glucotrack’s implantable CBGM technology.
The patents protect innovations in sensor chemistry, intravascular lead design, and low-power electronics, all integral to the company’s implantable system.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.